



## 臺北醫學大學 泌尿腎臟研究中心 會議記錄

時間：**114 年 3 月 13 日(星期四) 9:00-10:00**

地點：視訊會議-（請以正式全名登入會議室，以利進行會議簽到）

使用 Google Meet (會議前 10 分鐘即開啟會議室)

會議室連結：<https://meet.google.com/ihn-wugo-jfv>

(敬略稱位)

會議主席：洪冠予

與會人員：

【附醫】劉明哲、葉劭德、吳建志、林孝友、吳政誠、張景欣、林敬哲、吳致寬、方德昭、吳逸文、陳錫賢、林彥仲、高治圻、陳靜怡、葉曙慶、邵月珠、周安琪

【萬芳】溫玉清、李良明、林克勳、林雍偉、蕭志豪、許軒豪、賴宗豪、鍾卓興、許永和、鄭仲益、陳作孝、劉崇德、楊韻紅、吳岳霖

【雙和】吳佳璋、陳冠州、劉家宏、江怡德、鄒凱亦、高偉棠、胡書維、董勁偉、陳至亨、吳美儀、李明哲、洪麗玉、鄭彩梅、廖家德、高芷華、林冠宏、陳正憲、邱惠雯

【新國民】蘇裕謀、鄒居霖

長官指導：

吳麥斯校長、許志成教授、陳瑞明所長、盧星華副院長、  
許永和副院長


議程：

一、腎臟泌尿精準健康計畫及生物檢體資料庫進度報告(吳逸文主任)

二、團隊報告

1.功能性泌尿團隊(萬芳許軒豪醫師)

2.急性腎病團隊(雙和林冠宏醫師)






臺北醫學大學  
TAIPEI MEDICAL UNIVERSITY

## 腎臟泌尿精準健康計畫及生物檢體資料庫進度報告

報告人：吳逸文 副教授

114年3月13日

### 精準腎臟健康計畫進度：



[https://docs.google.com/forms/d/e/1FAIpQLSeWgJ5cNSuaBjDkuUtrRfqUY7G5mW43UIG8jxj49kic9c5Sw/viewform?usp=pp\\_url&entry.1813552769=T20241105-01](https://docs.google.com/forms/d/e/1FAIpQLSeWgJ5cNSuaBjDkuUtrRfqUY7G5mW43UIG8jxj49kic9c5Sw/viewform?usp=pp_url&entry.1813552769=T20241105-01)

Biobank 收案時，公衛學生同時收集問卷

附醫	雙和	萬芳
高治圻	林冠宏	吳岳霖
吳逸文	廖家德	

# One campus: 共同收案，共享資料，共同發表



## • Prospective Genomic Cohort Establishment:



高治忻/吳逸文



廖家德/林冠宏



吳岳霖

IgA nephropathy

Polycystic kidney disease

Other kidney disease

Diabetic kidney disease

年度	月份	腎臟科_雙和_血液	腎臟科_附醫_血液	腎臟科_萬芳_血液	腎臟科_雙和_尿液	腎臟科_附醫_尿液	腎臟科_萬芳_尿液	問卷_雙和	問卷_附醫	問卷_萬芳
2024	7	0	1	0	0	0	0	0	0	0
2024	8	0	2	0	0	0	0	0	0	0
2024	9	0	7	0	0	0	0	0	0	0
2024	10	0	13	0	0	0	0	0	0	0
2024	11	0	11	0	0	0	0	0	0	0
2024	12	0	18	0	0	0	0	0	0	0
2025	1	0	12	0	0	0	0	0	0	0
2025	2	0	10	1	0	0	0	0	10	0

## 目前成果及未來工作



### 成果：

- 教育部深耕計畫：腎病精準醫學計畫（吳逸文, 2024/1-2024/12）
- 國際研討會：台灣腎臟醫學會-台馬泰國際研討會（吳逸文, 2024/12/14）
- 論文：Polygenic Score for Kidney Function and Clinical Management through Whole Exome Sequencing in the Taiwanese Population (已投搞)
- 計畫：國科會：2件（吳逸文，洪冠宇，已投出），教育部深耕計畫：1件（吳逸文，已投出）

### 未來工作：

國衛院計畫：1件（吳麥斯，預計2025/03投出）

# 泌尿腎臟研究中心

## RCUK

組別：功能性泌尿團隊  
報告人: 萬芳醫院 許軒豪醫師  
20250313



## 分析因膀胱纖維化導致膀胱功能損害之研究

- 研究背景: 膀胱纖維化導致功能失常，導致間質性膀胱炎/膀胱疼痛症候群
- 研究目的: 藉由分析結抗膀胱纖維化的pathway，找出可以間質性膀胱炎/膀胱疼痛症候群的藥物



Original article



Therapeutic effect of modulating the NLRP3-regulated transforming growth factor- $\beta$  signaling pathway on interstitial cystitis/bladder pain syndrome

Hung-Jen Shih <sup>a,b,c</sup>, Chao-Yuan Chang <sup>d,e,f</sup>, Chung-Howe Lai <sup>a,1</sup>, Chun-Jen Huang <sup>d,e,f,\*</sup>,<sup>1</sup>

<sup>a</sup> Department of Urology, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan

<sup>b</sup> Department of Urology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan

<sup>c</sup> Department of Urology, Changhua Christian Hospital, Changhua, Taiwan


<sup>d</sup> Integrative Research Centre for Critical Care, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan

<sup>e</sup> Department of Anesthesiology, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan

<sup>f</sup> Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan

## Results & Conclusion

- The pathogenesis of chronic inflammation -induced IC/BPS is associated with the NLRP3 inflammasome /IL-1 $\beta$ -related TGF - $\beta$ /Smad pathway.
- Downregulation of the expression of this pathway through curcumin mitigates chronic inflammation -induced bladder injury .




# Medication for BPH

- Preventing or reducing bladder tissue remodeling in a timely manner is the treatment goal of BOO because delay treatment may induce irreversible bladder damage
  - A novel therapy that can stop or reverse bladder remodeling is in need for effective therapy of BOO.

## Two types of medications are available for treating BPH

### Medicines that shrink the prostate (5- $\alpha$ reductase inhibitors)<sup>3,7</sup>


- Relieve obstruction and symptoms
- Reduce prostate size and therefore, the risk of acute urinary retention and surgery



Shrinks the prostate

### Medicines that relax the muscles ( $\alpha$ -blockers)<sup>3,7</sup>

- Relieve the obstruction and improve symptoms
- Do not reduce prostate size




Relaxes the prostate muscles

北醫六十 邁向榮耀


6

# A novel cytokine inhibiting therapy : KCF-18

- KCF18 is a designed peptide which composed of 18 amino acids derived from the receptors of the TNF- $\alpha$ , IL-1 $\beta$  and IL-6.
  - The composition of KCF18 is N-terminal amino acids from TNF receptor-1, middle amino acids from IL-1 receptor and C-terminal amino acids from IL-6 receptor.
  - The anti-inflammatory effects of KCF18 have been confirmed in *in vitro* and *in vivo* studies.
- This novel peptide may serve as an effective anti-inflammatory treatment for BOO-induced bladder remodeling



## Enhance biodistribution in bladder



23



臺北醫學大學  
泌尿腎臟研究中心  
TMU Research Center of  
Urology and Kidney

## 急性腎病團隊 AKI-AKD bundle and oXiris

報告人：林冠宏 醫師

114.03.13



# Outline

- AKI-AKD bundle
- oXiris

1



*Nephrol Dial Transplant*, 2025, **40**, 524–536  
<https://doi.org/10.1093/ndt/gfae168>  
Advance access publication date: 17 July 2024

## A novel real-time model for predicting acute kidney injury in critically ill patients within 12 hours

Tao Sun ,<sup>1,\*</sup> Xiaofang Yue<sup>1,\*</sup>, Xiao Chen<sup>1,\*</sup>, Tiancha Huang<sup>2\*</sup>, Shaojun Gu<sup>1</sup>, Yibing Chen<sup>3</sup>, Yang Yu<sup>1</sup>, Fang Qian<sup>1</sup>, Chunmao Han ,<sup>1</sup>, Xuanliang Pan<sup>1</sup>, Xiao Lu<sup>1</sup>, Libin Li<sup>1</sup>, Yun Ji<sup>1</sup>, Kangsong Wu<sup>1</sup>, Hongfu Li<sup>1</sup>, Gong Zhang<sup>1</sup>, Xiang Li<sup>1</sup>, Jia Luo<sup>2</sup>, Man Huang<sup>1,2</sup>, Wei Cui<sup>1</sup>, Mao Zhang ,<sup>1</sup> and Zhihua Tao<sup>1</sup>

<sup>1</sup>The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China

<sup>2</sup>Chongqing Zhongyuan Huiji Biotechnology Co. Ltd, Chongqing, China

<sup>3</sup>Key Laboratory of Multiple Organ Failure (Zhejiang University), Ministry of Education, Hangzhou, China

Correspondence to: Zhihua Tao. E-mail: zrth@zjhu.edu.cn

\*These authors contributed equally to this work

## Artificial intelligence-enabled decision support in nephrology

Tyler J. Loftus, Benjamin Shickel, Tezcan Ozrazgat-Baslanti, Yuanfang Ren, Benjamin S. Glicksberg, Jie Cao, Karandeep Singh, Lili Chan, Girish N. Nadkarni & Azra Bihorac


*Nature Reviews Nephrology* **18**, 452–465 (2022) | [Cite this article](#)

3

### Box 1 | AI algorithms and applications frequently used in healthcare

<b>Types of health data</b>	Discriminant analysis Naive Bayes Support vector machine Decision trees Random forest Gradient boosting machines Neural networks • Convolutional neural networks • Recurrent neural networks
Structured data	
• Demographics	
• Laboratory tests	
• Medications	
• Diagnoses	
• Procedures	
Unstructured data	
• Clinical notes	
• Waveform data	
• Images	
• Videos	
<b>Types of AI</b>	<b>Applications</b>
Unsupervised learning	Biomarker discovery
Supervised learning	Drug discovery
Reinforcement learning	Disease diagnosis
<b>Algorithms</b>	• CheXNet
Generalized linear models	• Diabetic retinopathy
	• Skin cancer
	• Breast cancer nodal metastasis
	Patient risk stratification
	Treatment recommendation systems

4



5



# ICU team sepsis bundle care

ORIGINAL ARTICLE

## Early Goal-Directed Therapy in the Treatment of Severe Sepsis and Septic Shock

Authors: Emmanuel Rivers, M.D., M.P.H., Bryant Nguyen, M.D., Suzanne Havstad, M.A., Julie Ressler, B.S., Alexandria Muzzin, B.S., Bernhard Knoblich, M.D., Edward Peterson, Ph.D., and Michael Tomlanovich, M.D., for the Early Goal-Directed Therapy Collaborative Group\*. Author Info & Affiliations

Published November 8, 2001 | N Engl J Med 2001;345:1368-1377 | DOI: 10.1056/NEJMoa010307  
VOL\_345 NO\_19 | Copyright © 2001

**Protocolised Management In Sepsis (ProMISe): a multicentre randomised controlled trial of the clinical effectiveness and cost-effectiveness of early, goal-directed, protocolised resuscitation for emerging septic shock**

Health Technology Assessment, No. 19.97

Paul R Mouncey, Tiffany M Osborn, G Sarah Power, David A Harrison, M Zia Sadique, Richard D Grieve, Rahi Jahan, Jermaine CK Tan, Sheila E Harvey, Derek Bell, Julian F Bion, Timothy J Coats, Mervyn Singer, J Duncan Young, and Kathryn M Rowan.

\* Author Information and Affiliations

Southampton (UK): NIHRS Journals Library; 2015 Nov.

Review > Kidney Int. 2019 Jul;96(1):52-57. doi: 10.1016/j.kint.2018.11.047. Epub 2019 Mar 4.



## Fluid management in the critically ill

Jean-Louis Vincent <sup>1</sup>

13




## Initiation of oXiris



14

## Initiation of oXiris flow chart



16

## Conclusion

- AI輔助警示需兼顧sensitivity and specificity，才能最大化發現迫在眉睫的AKI病人與最小化醫療單位警示疲乏。
- 利用腎內AKI-AKD bundle 警示系統和重症加護單位sepsis bundle 系統，早期找出適合oXiris治療的病人。

17